Indiana Trust & Investment Management CO raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.0% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 23,520 shares of the biopharmaceutical company’s stock after acquiring an additional 451 shares during the quarter. Indiana Trust & Investment Management CO’s holdings in Pfizer were worth $852,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Security Asset Management grew its stake in shares of Pfizer by 125.6% in the fourth quarter. Security Asset Management now owns 28,838 shares of the biopharmaceutical company’s stock valued at $1,062,000 after buying an additional 16,056 shares in the last quarter. Sowell Financial Services LLC grew its stake in shares of Pfizer by 5.1% in the fourth quarter. Sowell Financial Services LLC now owns 309,093 shares of the biopharmaceutical company’s stock valued at $11,378,000 after buying an additional 15,071 shares in the last quarter. Wellington Shields Capital Management LLC grew its stake in shares of Pfizer by 7.6% in the fourth quarter. Wellington Shields Capital Management LLC now owns 104,766 shares of the biopharmaceutical company’s stock valued at $3,856,000 after buying an additional 7,405 shares in the last quarter. State of Wisconsin Investment Board grew its stake in shares of Pfizer by 18.1% in the fourth quarter. State of Wisconsin Investment Board now owns 6,040,242 shares of the biopharmaceutical company’s stock valued at $222,341,000 after buying an additional 924,796 shares in the last quarter. Finally, Sound Income Strategies LLC grew its stake in shares of Pfizer by 34.5% in the fourth quarter. Sound Income Strategies LLC now owns 119,776 shares of the biopharmaceutical company’s stock valued at $4,409,000 after buying an additional 30,750 shares in the last quarter. 67.36% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE PFE traded up $0.09 during midday trading on Thursday, reaching $36.00. The company’s stock had a trading volume of 255,480 shares, compared to its average volume of 32,556,707. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.13 and a current ratio of 1.40. Pfizer Inc. has a fifty-two week low of $31.61 and a fifty-two week high of $43.08. The business’s 50 day moving average price is $35.06 and its two-hundred day moving average price is $36.58. The company has a market cap of $200.79 billion, a P/E ratio of 23.17, a P/E/G ratio of 2.79 and a beta of 0.70.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 2nd. The biopharmaceutical company reported $0.42 earnings per share for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.04). Pfizer had a net margin of 17.85% and a return on equity of 24.88%. The business had revenue of $11.68 billion during the quarter, compared to analyst estimates of $11.32 billion. During the same quarter in the previous year, the firm posted $0.55 earnings per share. The firm’s quarterly revenue was up 11.8% on a year-over-year basis. Sell-side analysts forecast that Pfizer Inc. will post 2.89 earnings per share for the current fiscal year.

A number of research firms have commented on PFE. TheStreet cut shares of Pfizer from a “b” rating to a “c+” rating in a research report on Friday, March 5th. Berenberg Bank reaffirmed a “neutral” rating and set a $38.00 target price on shares of Pfizer in a report on Tuesday, March 23rd. JPMorgan Chase & Co. set a $36.00 price target on shares of Pfizer and gave the company a “neutral” rating in a research note on Wednesday, February 3rd. DZ Bank restated a “buy” rating and set a $41.00 price objective on shares of Pfizer in a research report on Wednesday, February 3rd. Finally, Royal Bank of Canada started coverage on shares of Pfizer in a research report on Wednesday. They set a “sector perform” rating and a $42.00 price objective for the company. Eleven research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $38.47.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.

Featured Story: VIX – Volatility Index

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.